Wojciech Jurczak

Research interests

Publications

• Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2300696

• Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.23.00562

• Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00293-5

• Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2211582

• Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.21.01210

• Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00224-5

• ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.19.03355

• A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

  Blood · 2020 · https://doi.org/10.1182/blood.2020006844

• Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)30262-2

• Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.02403

• Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)32984-2

• Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.76.6840

• Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)33108-2

• Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1708984

• Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30019-5

• Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.59.2782

• Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)00667-4

• PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1314583

• Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1306220

Current projects

No projects listed.